SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
The company says the product will now be distributed exclusively through Anovo Specialty Pharmacy
Bidding window open till May 15; study to map costs and bottlenecks across pharma supply chains
The acquisition aims to bolster Merck’s hematology portfolio with Terns’ lead oncology candidate, TERN-701
The agreement will combine Biocytogen’s cutting-edge fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive drug development
Enthral.ai’s platform integrates AI-driven capabilities with compliance-first architecture, enabling automated training workflows
This marks a meaningful step in the company's continued expansion in the region
The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio
KeyCi’s dermatologically tested lineup emphasizes clean formulations—vegan, cruelty-free, alcohol-free, and paraben-free—while being backed by pharmaceutical-grade research and FDA approval
Subscribe To Our Newsletter & Stay Updated
